New combo aims to outsmart Platinum-Resistant ovarian cancer

NCT ID NCT07109414

Ongoing Disease control Sponsor: Novita Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called NP-G2-044 (Prilukae) combined with standard chemotherapy (PLD) in people with ovarian cancer that no longer responds to platinum-based treatments. About 380 participants will receive either the combo or PLD alone to see if the combination improves tumor shrinkage and delays cancer growth. The trial also checks for side effects and aims to find the best dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NP-G2-044 (Prilukae) and pegylated liposomal doxorubicin (PLD)
What this could lead to: If successful, this combination could offer a new treatment option that slows cancer growth and improves response rates for people with platinum-resistant ovarian cancer.
What could go wrong: This is an early-to-mid-stage trial, so the combination may not prove more effective than PLD alone. Side effects from the drugs could also limit tolerability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN HIGH-GRADE SEROUS CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian carcinoma ovarian serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLATINUM-RESISTANT OVARIAN CANCER

Contacts and locations

Locations

HonorHealth Cancer Care

Phoenix, Arizona, 85016, United States
Optimum Clinical Research Group, LLC

Albuquerque, New Mexico, 87109, United States
Trials365

Shreveport, Louisiana, 71133, United States
University Of Wisconsin Carbone Cancer Center

Madison, Wisconsin, 53792-9988, United States
University of Pennsylvania Health System, Perelman Center for Advanced Medicine

Philadelphia, Pennsylvania, 19104-5127, United States
Utah Cancer Specialists

Salt Lake City, Utah, 84106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.